AxoGen (NASDAQ:AXGN) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of AxoGen (NASDAQ:AXGN - Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $24.00 price target on the medical equipment provider's stock.

Separately, Canaccord Genuity Group lifted their price objective on shares of AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $20.75.

AxoGen Trading Down 0.2 %

Shares of NASDAQ:AXGN traded down $0.04 during trading on Wednesday, hitting $17.73. 636,905 shares of the company's stock were exchanged, compared to its average volume of 557,396. AxoGen has a 1-year low of $5.55 and a 1-year high of $21.00. The firm has a 50-day moving average price of $17.92 and a two-hundred day moving average price of $15.33. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The firm has a market cap of $786.22 million, a P/E ratio of -55.41 and a beta of 1.02.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of AxoGen stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the transaction, the director now owns 97,899 shares of the company's stock, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 7.00% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AXGN. First Light Asset Management LLC raised its holdings in shares of AxoGen by 10.2% in the fourth quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider's stock valued at $74,272,000 after purchasing an additional 416,499 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of AxoGen by 3.2% in the third quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider's stock valued at $14,170,000 after purchasing an additional 31,612 shares during the last quarter. Driehaus Capital Management LLC raised its holdings in shares of AxoGen by 166.0% in the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider's stock valued at $15,729,000 after purchasing an additional 595,579 shares during the last quarter. State Street Corp raised its holdings in shares of AxoGen by 11.9% in the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider's stock valued at $12,571,000 after purchasing an additional 95,051 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of AxoGen by 13.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider's stock valued at $12,735,000 after purchasing an additional 91,984 shares during the last quarter. Institutional investors own 80.29% of the company's stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.